Literature DB >> 12768334

111In-DOTA- dPhe1-Tyr3-octreotide, 111In-DOTA-lanreotide and 67Ga citrate scintigraphy for visualisation of extranodal marginal zone B-cell lymphoma of the MALT type: a comparative study.

Shuren Li1, Amir Kurtaran, Mei Li, Tatjana Traub-Weidinger, Oskar Kienast, Wolfgang Schima, Peter Angelberger, Irene Virgolini, Markus Raderer, Robert Dudczak.   

Abstract

Somatostatin receptor (SSTR) scintigraphy and gallium-67 citrate ((67)Ga) scintigraphy have been used for visualisation of Hodgkin's lymphoma and non-Hodgkin's lymphoma. However, experience with B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) type is very limited. The aim of this study was to prospectively compare the (67)Ga scintigraphy results with those obtained by (111)In-DOTA- dPhe(1)-Tyr(3)-octreotide ((111)In-DOTA-TOCT) and (111)In-DOTA-lanreotide ((111)In-DOTA-LAN) scintigraphy in patients with proven MALT-type lymphoma. Comparative scintigraphic examinations using (67)Ga, (111)In-DOTA-TOCT and (111)In-DOTA-LAN were performed in 18 patients (11 female and 7 male, median age 64+/-15 years) with histologically verified MALT-type lymphomas of various origin. Planar and single-photon emission tomography imaging acquisitions were performed after injection of a mean dose of 185+/-26 MBq (67)Ga and 165+/-20 MBq (111)In-DOTA-TOCT or (111)In-DOTA-LAN. All scintigraphic results were correlated with other conventional examinations including gastroscopy, colonoscopy, endosonoscopy, ophthalmologic investigation, CT of the thorax and abdomen and bone marrow biopsy. This comparative study showed that (67)Ga scintigraphy found abnormalities in 10 of 16 patients (63%) and detected 18 of 31 clinically involved sites (58%), but was false positive in three patients. (111)In-DOTA-TOCT found abnormalities in 9 of 15 patients (60%) and detected 15 of 27 clinical lesions (56%); it was false positive in two patients. (111)In-DOTA-LAN scintigraphy showed abnormalities in 7 of 11 patients (64%) and found 12 of 22 clinical lesions (55%). False-positive (111)In-DOTA-LAN scan results were found in two patients. For supra-diaphragmatic lesions, (67)Ga scintigraphy detected 12 of 16 sites (75%). (111)In-DOTA-TOCT scintigraphy revealed 7 of 15 lesions (47%). (111)In-DOTA-LAN showed 6 of 12 positive sites (50%). For infra-diaphragmatic involvement, the sensitivities of (67)Ga, (111)In-DOTA-TOCT and (111)In-DOTA-LAN were 40%, 67% and 60%, respectively. It is concluded that MALT-type lymphoma can be visualised by (67)Ga, (111)In-DOTA-TOCT and (111)In-DOTA-LAN scintigraphy. Although there were no statistically significant differences in patient-related and site-related sensitivities when using (67)Ga compared with (111)In-DOTA-TOCT and (111)In-DOTA-LAN, the sensitivity of (67)Ga tended to be superior to that of (111)In-DOTA-TOCT and (111)In-DOTA-LAN for supra-diaphragmatic lesions but inferior for infra-diaphragmatic involvement. In selected cases, the combination of (67)Ga and (111)In-DOTA-LAN or (111)In-DOTA-TOCT may increase the diagnostic efficiency in patients with MALT-type lymphoma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12768334     DOI: 10.1007/s00259-003-1206-1

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  24 in total

1.  Somatostatin receptor expression in primary gastric versus nongastric extranodal B-cell lymphoma of mucosa-associated lymphoid tissue type.

Authors:  M Raderer; J Valencak; F Pfeffel; J Drach; T Pangerl; A Kurtaran; M Hejna; F Vorbeck; A Chott; I Virgolini
Journal:  J Natl Cancer Inst       Date:  1999-04-21       Impact factor: 13.506

Review 2.  From the R.E.A.L. Classification to the upcoming WHO scheme: a step toward universal categorization of lymphoma entities?

Authors:  S A Pileri; M Milani; G Fraternali-Orcioni; E Sabattini
Journal:  Ann Oncol       Date:  1998-06       Impact factor: 32.976

3.  The relevance of somatostatin receptor expression in malignant lymphomas.

Authors:  P J van den Anker-Lugtenburg; B Löwenberg; S W Lamberts; E P Krenning
Journal:  Metabolism       Date:  1996-08       Impact factor: 8.694

4.  DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy.

Authors:  P M Smith-Jones; C Bischof; M Leimer; D Gludovacz; P Angelberger; T Pangerl; M Peck-Radosavljevic; G Hamilton; K Kaserer; A Kofler; H Schlangbauer-Wadl; T Traub; I Virgolini
Journal:  Endocrinology       Date:  1999-11       Impact factor: 4.736

5.  Abdominal staging of thoracic Hodgkin disease: CT-lymphangiography-Ga-67 scanning correlation.

Authors:  P C Stomper; S P Cholewinski; J Park; S P Bakshi; M P Barcos
Journal:  Radiology       Date:  1993-05       Impact factor: 11.105

6.  Clinical relevance of gallium-67 scintigraphy in lymphoma before and after therapy.

Authors:  C Delcambre; O Reman; M Henry-Amar; A M Peny; M Macro; S Cheze; J Y Génot; A Tanguy; O Switsers; H L Van; J E Couëtte; M Leporrier; S Bardet
Journal:  Eur J Nucl Med       Date:  2000-02

Review 7.  Somatostatin receptor imaging.

Authors:  Dik J Kwekkeboom; Eric P Krenning
Journal:  Semin Nucl Med       Date:  2002-04       Impact factor: 4.446

Review 8.  Experience with indium-111 and yttrium-90-labeled somatostatin analogs.

Authors:  I Virgolini; T Traub; C Novotny; M Leimer; B Füger; S R Li; P Patri; T Pangerl; P Angelberger; M Raderer; G Burggasser; F Andreae; A Kurtaran; R Dudczak
Journal:  Curr Pharm Des       Date:  2002       Impact factor: 3.116

9.  Low sensitivity of computed tomography in the staging of gastric lymphomas of mucosa-associated lymphoid tissue: impact on prospective trials and ordinary clinical practice.

Authors:  A J Ferreri; M Ponzoni; S Cordio; A Vanzulli; E Garuti; E Viale; E Villa
Journal:  Am J Clin Oncol       Date:  1998-12       Impact factor: 2.339

10.  Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy.

Authors:  M de Jong; W H Bakker; E P Krenning; W A Breeman; M E van der Pluijm; B F Bernard; T J Visser; E Jermann; M Béhé; P Powell; H R Mäcke
Journal:  Eur J Nucl Med       Date:  1997-04
View more
  2 in total

1.  Differential somatostatin and CXCR4 chemokine receptor expression in MALT-type lymphoma of gastric and extragastric origin.

Authors:  Susann Stollberg; Daniel Kämmerer; Elisa Neubauer; Stefan Schulz; Ingrid Simonitsch-Klupp; Barbara Kiesewetter; Markus Raderer; Amelie Lupp
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-20       Impact factor: 4.553

Review 2.  Managing lymphoma with non-FDG radiotracers: current clinical and preclinical applications.

Authors:  Fan-Lin Kong; Richard J Ford; David J Yang
Journal:  Biomed Res Int       Date:  2013-06-06       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.